medigraphic.com
ISSN 0016-3813 (Print)

2004, Number 6

<< Back Next >>

Gac Med Mex 2004; 140 (6)

Do the World Medical Association and other international organisations lack ethics?

García-Romero H, Casas- Martínez ML

Language: Spanish
References: 34
Page: 667-670
PDF size: 29.38 Kb.


Text Extraction

No abstract


REFERENCES

  1. Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med 1997;337:853-856.

  2. Macklin R. Investigación colaborativa internacional: acontecimientos recientes. En: Pellegrini FA, Macklin R, editores. Programa regional de bioética. Organización Panamericana de la Salud. Organización Mundial de la Salud;1999. pp. 47-61.

  3. Connor EM, Sperling RS, Geller R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type I with zidovudine treatment. New Engl J Med. 1994;331;1173-1180.

  4. Buchholz B, Gruber T, Marcus U, y cols. German-Austrian recommendations for HIV-therapy in pregnancy: update May 2003. Eur J Med Res 2004;9:287-303.

  5. Levine RJ. The best proven therapeutic method standard in technical trials in technologically developing countries. IRB: a Review of Human Subjects Research. 1998;20:6.

  6. Beauchamp T, Childress JF. Principles of biomedical ethics. 5a ed. Oxford, UK: Oxford University Press;2001.

  7. Asociación Medica Mundial. Declaración de Helsinki. 1964. 2000. Edimburgo, Escocia. Reproducida en Bol Acad Nac Mex Bioetica (ANMB) 2004;4:37-40.

  8. Miller FG. Placebo-controlled trials in psychiatric research: an ethical perspective. Biol Psychiatry 2000;47:707-716.

  9. Asociación Médica Mundial. Declaración de Helsinki. 1964-2000. Edimburgo, Escocia. Clarificación del párrafo 29. 2002. Washington, D.C., USA: Reproducida en el Bol Acad Mac Mex Bioetica (ANMB) 2004;4:39-40.

  10. Asociación Médica Mundial. Declaración de Ginebra. 1948, enmendada por la 22a Asamblea. Sydney, Australia. 1968.

  11. Jackson J B, Musoke P, Fleming T, y cols. Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of mother to child transmission of HIV-1 in Kampala, Uganda: 18 month follow-up of the HIVNET 0/2 randomised trial. Lancet 2003;362:859-856.

  12. Shafter N, Chvachoowong R, Mock PA, y cols. Short course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999;353:773-780.

  13. Leroy V, Karon JM, Alioum A, y cols. Postnatal transmission of HIV-1 after a maternal short-course zidovudine peripartum regime in West Africa. AIDS 2003;17:1493-501.

  14. Leroy V, Karon JM, Alioum A, y cols. Op. cit. pp. 1493-501.

  15. Bardeguez AD, Shapiro DE, Mofenson LM, y cols. Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. JAIDS 2003;32-170-181.

  16. Cochrane Database of Systemic Reviews (3), CD 003256. 2003.

  17. De Jesús E, Wald A, Warren T, y cols. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003:188:1009-16.

  18. Colibaly-Traore D, Mselati P, Vidal L, y cols. The Ditrame Clinical Trial aimed at reducing the mother-child transmission of HIV in Abidjian. Participants understanding of the trial principles. Presse-Medicale 2003;32:343-350.

  19. Tafesse E, Murphy T. Letter. N Engl J Med 1998;338:838.

  20. Lavori PW. Placebo control group in randomized treatment trials: a statistician's perspective. Biol Psychiatry 2000;47:717-23.

  21. Garber DA, Silvestri G, Feinberg MB. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis 2004;4:397-413.

  22. Pitisuttithum P, Nitayaphan S, y cols. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Diseases 2003;188:219-227.

  23. Cao H, Kaleebe P, Horn D, y cols. Immunogenicity of a recombinant human immunodeficiency virus (HIV) canary-pox vaccine in HIV-seronegative Ugandan results of the HIV Network for Prevention Trials 007 Vaccine Study. J Infect Dis 2003;187:887-895.

  24. Organización Mundial de la Salud. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva, Switzerland: Council for International Organizations of Medical Science;1993.

  25. Brody BA. Philosophical reflections on clinical trials in developing countries. En: Rhode E, y cols, editores. Medical and social justice. Oxford, UK: Oxford University Press;2002. pp. 197-205.

  26. Ruiz-Manero C. El negocio de la salud. La Jornada 2004;322(22):12.

  27. Greider K. The bit fix: how the pharmaceutical industry rips off American consumers. Public Affairs Books;2003.

  28. Datos informados por Farmacias Similares. Desplegado. La Jornada, 13 de julio. 2004.

  29. Nuffield Council on Bioethics: Ética de la investigación relativa a la atención sanitaria en los países en desarrollo. Nuffield, Council on Bioethics;2002. pp. 1-17.

  30. Macklin R. Ref. (2). Op. cit. pp. 56-8.

  31. Consejo de Organizaciones Internacionales de las Ciencias Médicas (CIOMS), en colaboración con la Organización Mundial de la Salud: Pautas éticas internacionales para la investigación biomédica en seres humanos. Antecedentes. Ginebra, Switzerland: 2002. Chile: LOMS;Mayo 2003. pp. 11-15.

  32. CIOMS. Op. cit. pp. 21-22.

  33. CIOMS. Op. cit. Pauta II y Comentarios. Pp. 59-661.

  34. Tealdi JC. Ética de la investigación: el principio y el fin de la bioética. Summa Bioética. Num. Esp. Año 1. Septiembre 2003. pp. 69-74.




2020     |     www.medigraphic.com